Urinary dysfunction is a common feature and may often be a presenting symptom of neurological conditions including spinal cord injury, stroke, multiple sclerosis, spina bifida, cerebral palsy, and Parkinson disease. Such dysfunction leads to morbidity and decreased quality of life for patients with these conditions. The diagnosis and treatment of neurogenic urinary dysfunction is complex, dynamic, and multifaceted. An individualized management strategy, incorporating medical, educational, and psychosocial components, is required to achieve optimum outcomes for patients and their caregivers. Accurate diagnosis, referral for urological assessment, and selection of the most appropriate treatment are vital in ensuring that the individual patient has the best possible outcome and improvement in quality of life. In view of these facts, nurses play a key role in ensuring that patients with neurogenic urinary dysfunction receive the assessment and treatment they need. In addition, the nursing role in the monitoring of treatment and educational support for patients and their caregivers is a strong driver of successful management.
U rinary tract dysfunction is a very common problem in patients with underlying neurologic conditions such as stroke (Chan, 1997) , multiple sclerosis (MS; Betts, D'Mellow, & Fowler, 1993; DasGupta & Fowler, 2003; Goldstein, Siroky, Sax, & Krane, 1982; Pappalardo, Patti, & Reggio, 2004; Rashid & Hollander, 1998; Schulte-Baukloh et al., 2006) , Parkinson disease (Loran, Fedorova, Mazurenko, & Khitarishvili, 2006) , cerebral palsy (Karaman, Kaya, Caskurlu, Guney, & Ergenekon, 2005) , spinal cord injury (SCI) or disease (Ku, 2006; Schurch, 2000a) , and spina bifida (myelomeningocele; Verhoef et al., 2005) . In these patients, depending on the underlying condition, urinary symptoms are often the most distressing and disabling of symptoms experienced.
Neurogenic urinary dysfunction (also known as neurogenic bladder) is defined as lower urinary tract dysfunction because of disturbance of the neurological control mechanisms; it can only be diagnosed in the presence of neurological pathology. The most recent 2002 report of the International Continence Society included standard terms to better define clinical situations such as lower urinary tract dysfunction and also introduced several improvements in diagnostic categorization and classification .
Improvements include better distinction between symptoms, signs, urodynamic observations, and conditions; the subdivision of lower urinary tract symptoms into storage, voiding, and postvoiding symptoms; a new definition of urinary incontinence (any involuntary leakage of urine); and the new concept of nocturia (waking at night to urinate; Abrams et al., 2002; Schafer et al., 2002; van Kerrebroeck et al., 2002) . Clear and specific definitions allow easier classification of patients, which will help to standardize clinical trials and lead to improved treatment algorithms.
Unidentified or incorrectly diagnosed problems as well as inappropriate treatment or, even worse, lack of treatment of urinary dysfunction can result in renal damage and, ultimately, renal failure and death (Schurch, 2000b) . These patients are at higher risk of renal system complications such as bladder stones, urinary tract infection (UTI), pyelonephritis, reflux, diverticuli, and prolapse of the bladder. Lack of effective treatment and poor symptom control can ultimately lead to detrusor sphincter dyssynergia (where there is a loss of coordinated action between the bladder and the external sphincter muscle caused by damage to the nervous system; Castro-Diaz & Taracena Lafuente, 2006; Parratte et al., 2003) and sequelae such as UTI, reflux of urine into the kidney, pyelonephritis, and, ultimately, acute and chronic renal failure (Chancellor, Anderson, & Boone, 2006) .
Neurogenic urinary dysfunction also has significant adverse medical, economic, social, and personal impact on patients and caregivers, reduces quality of life (Ku, 2006; Schurch, 2000b) , and may often play a part in patients losing independence or potentially requiring institutionalization . Urinary incontinence, in particular, is a very common issue in the general population with an overall prevalence of 38% in women and 17% in men (Anger, Saigal, Stothers, et al., 2006) , although overall prevalence of overactive bladder is similar in men and women (Stewart et al., 2003) . Incontinence increases with age in both men and women, but severe incontinence in elderly men is about half that of women (Nitti, 2001; Thom, 1998) . Urinary incontinence and/or retention is an extremely common issue in patients with neurologic problems; 50%Y80% of patients with MS (Goldstein et al., 1982) , for example, and about 80% of patients with SCI have long-term urinary tract dysfunction (Ku, 2006) .
Urinary tract dysfunction is a major burden on healthcare resources. In 2000, the total healthcare cost of urinary incontinence was estimated at US$19.5 billion annually (US$14.2 billion for community residents and US$5.3 billion for nursing homes). Direct medical costs include those for medical care and incontinence-associated complications, whereas nonmedical indirect costs include absorbent products, laundry, and loss of productivity (Hu et al., 2004) . In patients with neurological conditions, the cost of neurogenic urinary dysfunction can be a major part of the total costs of care.
Consequently, the timely and effective management of neurogenic bladder is a vital part of any treatment strategy for patients with neurologic disorders. Nurses can have a positive impact on patients' quality of life by ensuring that patients' urological symptoms are recognized, assessed, and treated. Nurses are in a perfect position not only to ask direct questions regarding incontinence and retention but also to introduce the education needed to cope with negative feelings as well as the practical aspects of managing the condition. The role of the nurse in diagnosis, ongoing assessment, and monitoring of bladder function during treatment is a key part of the management of neurogenic urinary dysfunction. Diagnosis can be hindered by the patient's unwillingness to talk about their urinary issues; therefore, the nurse's role as a good listener is particularly important in diagnosis, work-up, and monitoring. Sensitive but frank discussion highlighting the prevalence of this problem helps to dispel fear and embarrassment. Therefore, it is important for nurses to have an awareness of appropriate assessment techniques and treatment options (Woodward, 2004) .
Urological and Urodynamic Assessment
Urinary problems can include those related to storage/ capacityVdetrusor overactivity (urge incontinence, urinary frequency, nocturia, and urgency), the more common presentation in neurogenic urinary dysfunction; those related to emptying/complianceVunderactivity (urinary retention or incomplete emptying); or a combination of both (Nitti, 2001) . Incomplete emptying can be a result of poor pelvic floor support and subsequent prolapse of the bladder related to muscle weakness frequently seen in those with neurologic issues. It is important to remember that these problems can be superimposed on preexisting problems such as those related to childbirth, diabetic neuropathy, or benign prostatic hypertrophy (BPH), and the work-up should include looking for common issues that impact everyone as well as urinary symptoms related to the underlying neurological condition.
The most common form of bladder dysfunction related to most neurological conditions is that of detrusor overactivity (Fowler & O'Malley, 2003) . After stroke, as with SCI, a patient can experience two phases of bladder dysfunction (Gross, 1992) : temporary acute cerebral shockVdetrusor underactivity, which causes urinary retention, and subsequent detrusor overactivity, which causes urinary frequency, urgency, and urge incontinence.
Nurses should focus their assessment questions in this population on urgency/frequency symptoms and stream characteristics, although symptoms of stress incontinence are frequently elicited during the discussion. Urinary incontinence can be defined by an affirmative response to one of two questions: BDuring the past month have you ever experienced urine loss (wet yourself) when coughing, laughing, or doing some other activity[ and BDuring the past month have you ever had to pee and then wet yourself before getting to the toilet?[ (as adapted by Swanson, Kaczorowski, Skelly, & Finkelstein, 2005 ; from the original questions evaluated by Lagro-Janssen, Debruyne, & van Weel, 1991 stress and urge incontinence (Lagro-Janssen et al., 1991; Swanson et al., 2005) . Questions relating to urinary retention should also be posed, including those to identify a weak or trickling stream, any difficulty initiating the stream, a need to bear down or bend over or push on the belly to help empty bladder, a stream that is intermittent or stops or starts, or a sensation of incomplete emptying. The diagnosis of urinary retention is confirmed by a postvoid residual (PVR) measurement of more than 100Y150 ml of urine as shown by straight catheterization or bladder scan. An elevated PVR (9100 ml) can also indicate diabetes or neurologic abnormalities and can result in chronic UTIs associated with hematuria. Symptoms alone may not always provide sufficient information for diagnosis; for example, in patients with bladder overactivity and incomplete emptying, other investigations will be required for accurate diagnosis (Ku, 2006) . Therefore, referral for thorough urological assessment is vital in patients who have not responded to treatment; in those with previous history of surgery, pain, or bleeding; and in cases where there is potential for reflux. Patients should be referred for initial urological assessment when retention is discovered to assess the condition of kidneys and to ascertain whether damage has already occurred. Repeated assessment should be performed every few years or sooner in patients with changes in condition, in those with previously diagnosed neurologic disease, and in those with recurrent UTI or a high potential for reflux.
The types of recommended urological assessments, together with rationale for testing, expected findings, and recommended frequency, are shown in Table 1 .
For urodynamic pressure-flow assessment, the objective is to fill the bladder and to try to evoke leaking. Urodynamic studies provide useful information regarding the size, the stretch, and the stability of the bladder and can be combined with cystoscopy and imaging studies (static and voiding cystometrogram, fluoroscopy, renal ultrasound, and intravenous pyelogram) to provide a comprehensive clinical picture. Urodynamic tests last roughly 30Y45 minutes, and the patient may eat before the test. No intravenous administration is needed, and a very small diameter catheter is used to fill the bladder with normal saline or a contrast medium. Cystoscopy is often done at the same time as urodynamic assessments and is not only helpful in monitoring for stones and bladder cancer, particularly in patients with a long-term indwelling catheter who have a greater potential for urinary stones and malignancy, but also helps the urologist directly visualize the condition of the bladder wall in patients with longstanding high-pressure bladders. Fluoroscopy also provides a good indication of potential for urinary retention and is effective for monitoring the pathological formation of thick fibrous strands of muscle fibers (trabeculae) within the bladder wall. The degree of bladder trabeculation is useful in assessing the effectiveness of treatment of detrusor sphincter dyssynergia. Cystoscopy is useful for detecting both bladder and urethra diverticuli (herniations of the bladder or urethral mucosa through the detrusor muscle or urethral wall musculature).
Treatment Options
The goals of treatment of neurogenic urinary dysfunction are to preserve renal function and to improve patient quality of life by providing symptom relief and by reducing the risk of urological complications (Fowler & O'Malley, 2003) . A range of treatment options for neurogenic bladder are available to facilitate bladder storage and bladder emptying. The advantages and disadvantages of these treatments are shown in Table 2 (Ruggieri, Braverman, & Pontari, 2005) .
Treatment of neurogenic bladder dysfunction must take into account the severity of the underlying neurological condition, the potential risks for the upper urinary tract, and the expected quality of life (Schurch, 2000b) ; therefore, each patient must be considered on an individual basis (Ku, 2006) . A treatment algorithm is shown in Figure 1 (Fowler & O'Malley, 2003) .
Numerous additional factors will also affect the suitability of specific treatment for the individual patient with a neurological condition. These can include patient's living conditions, level of family or caregiver support, manual dexterity, and cognitive function. These factors may change over time and must be continually assessed to ensure that the most suitable treatment is being provided (Ku, 2006) .
The success of treatment is influenced by the motivation and compliance of the patient and caregivers and thus can be greatly influenced by sympathetic support, training, and education provided by the nurse. Lack of compliance (either intentional or unintentional) or incorrect or inadequate treatment is usually first detected by the nurse.
Bladder Storage Pharmacotherapy
Pharmacotherapy can be effective in patients with neurogenic detrusor overactivity (NDO). Anticholinergic agents comprise first-line pharmacotherapy in most patients; the mechanism of action of these agents is primarily relaxation of the detrusor muscle by mediating voluntary and involuntary detrusor muscle contractions. Anticholinergics inhibit bladder contractions and increase bladder capacity, thus relieving symptoms of urge incontinence, but are contraindicated in persons with uncontrolled narrow-angle glaucoma, myasthenia gravis, and urinary and gastric retention/obstruction. These medications can cause a range of side effects, the most common being dry mouth and constipation. Some anticholinergics such as oxybutynin and tolterodine have antispasmodic and muscarinic receptor antagonistic effects, which are also beneficial in reducing the symptoms of bladder overactivity. Antimuscarinic and !-adrenergic antagonists have different mechanisms of action and therefore may be combined to achieve an additive effect (Kim, Thomas, Smith, & Chancellor, 2006; ; however, in doing so, there is potential for increasing the incidence of adverse effects. Clinical evidence shows that the newer anticholinergics trospium and tolterodine are associated with fewer adverse effects than older agents such as oxybutynin (DasGupta & Fowler, 2003) .
Tricyclic antidepressants, such as imipramine and amitriptyline, decrease bladder contractility and increase urethral resistance, resulting in tightening of E15 the bladder neck (Cannon & Chancellor, 2003) , but use of these agents in bladder dysfunction is not approved by the U.S. Food and Drug Administration (FDA). A recent Cochrane review has questioned their use in children because of the occurrence of potentially serious adverse effects (Glazener, Evans, & Peto, 2003) . Estrogen receptors are distributed throughout the female bladder and urethra. Studies have evaluated systemic estrogen replacement therapy or supplementation and localized estrogen therapy with estradiol vaginal creams or an estradiol-impregnated vaginal ring (Estring A ) in postmenopausal women with mild-to-moderate incontinence. Estrogen has been shown to increase urethral and pelvic floor muscle tone and flexibility (Miodrag, Castleden, & Vallance, 1988) . However, recent studies have shown that hormone therapy may not be effective in incontinence (Palmer & Newman, 2007) .
Neuromodulation With Botulinum Toxin
Botulinum toxin A (BoNT-A) is a pharmacological neuromodulator that causes a graded (dose-dependent) weakening or decreased responsiveness of the detrusor muscle, which leads to alleviation of urologic symptoms. Selective injection of BoNT-A into the detrusor muscle has shown efficacy in the treatment of detrusor overactivity of neurogenic origin in adults (Schurch & Corcos, 2005) and also in pediatric patients (Altaweel, Jednack, Bilodeau, & Corcos, 2006; Schulte-Baukloh, Michael, Schobert, Stolze, & Knispel, 2002) , specifically in myelomeningocele (Kessler, Danuser, Schumacher, Studer, & Burkhard, 2005) . Although placebo-controlled studies in patients with NDO have demonstrated the efficacy of the Botox A formulation of BoNT-A, further placebo-controlled, blinded studies must be completed and efficacy determined before Botox can receive FDA approval for use in this indication, and until then, it will continue to be an Boff-label[ use (Figure 2) .
Appropriate candidates for Botox injections are patients with sensory and/or urge incontinence with 
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NDO and/or detrusor sphincter dyssynergia. Botox has typically been used after one has exhausted traditional oral therapies (sometimes at higher than approved doses); however, after initiation of Botox therapy, many patients may be able to reduce their oral medication (Reitz, Haferkamp, Wagener, Gerner, & Hohenfellner, 2006) . Botox has been shown to provide relief of symptoms in patients resistant to or unable to tolerate anticholinergic agents (Dykstra, Sidi, Scott, Pagel, & Goldish, 1988) . Potential risks associated with Botox injections include pain, hematuria, infection, urinary retention, and lack of effectiveness. Pain is a rare but potential symptom that may occur because of the injection process, lasting minutes to several hours after the procedure. This usually only occurs in patients with a history of a bladder pain syndrome or in patients who admit to neuropathic pain.
Hematuria may occur during the procedure but should not continue upon completion. Extra care should be taken in patients on anticoagulant therapies. Chronic aspirin use should be discontinued up to 2 weeks before the procedure. Patients on warfarin may need to be switched to a subcutaneous anticoagulant for several days before the procedure. Warfarin can usually be resumed in the evening after Botox injections. Patients need to be instructed that should passage of clots occur after the procedure, the office needs to be notified immediately.
A slight risk of infection exists because of the invasiveness of this procedure as Botox is injected into the detrusor muscle in 10Y30 sites. In all patients, and especially those with recurrent UTI, it is recommended to test the urine before any injections and treat as needed in patients who are colonized. Infection can develop days to weeks after the procedure, so patients must be instructed to watch for any signs and symptoms of infection.
Onset of effectiveness of Botox can vary from a sudden change within several days to a more slow insidious effect over a 4-week period. Patients should be instructed to monitor urinary frequency and urine flow as well as abdominal girth. Neurogenic patients who do not perform intermittent self-catheterization (ISC) should be instructed on this procedure as well as be informed about the potential that retention can occur and that ISC may be required. In that instance, an appropriate catheterization schedule would need to be determined. The risk of retention is slight in NDO patients; however, because it does exist, patients who cannot perform ISC may not be appropriate candidates for Botox injections. In patients with detrusor sphincter dyssynergia who already catheterize, retention is an intended result and often a higher dose of Botox may be used.
Patients should return to the office within 4 weeks so that efficacy can be established and retention assessed.
Effectiveness of Botox in the bladder may last from 6 to 9 months and sometimes up to 12 months. Repeated injections of Botox can be used to provide ongoing efficacy, but reinjection of Botox should not be performed sooner than every 3 to 4 months because of the risk of development of neutralizing antibodies and subsequent treatment resistance. Should a patient receive Botox to another area of the body for lower limb spasticity, for example, it may be prudent to space injections at least 4 to 6 months apart. The spacing of the Botox injections will depend on total body exposure to high doses (combined treatment doses) and antibody risk.
Some early open-label studies have shown that efficacy persists with repeated injections (Schurch, 2006) ; however, large long-term observational studies are required to confirm both efficacy and safety. The current evidence is that repeat injections are at least as effective as the first, providing persistent improvement, and do not lead to exacerbation of symptoms, drug tolerance, changes to bladder compliance, or detrusor fibrosis (Schurch, 2006) .
Treatment of Poor Bladder Emptying Intermittent Self-Catheterization
ISC is the preferred means of managing chronic retention, achieving the dual purpose of improving continence and (more importantly) preserving renal function (Borzyskowski, Cox, Edward, & Owen, 2004; Herr, 1975; Wyndaele, 2002) . UTIs are the most common complication of ISC, with previous indwelling catheter being a risk factor for chronic infection and urinary sepsis. Other complications include catheterization trauma, urethral strictures, false passages, prostatitis and, rarely, epididymitis and urethritis (Weld & Dmochowski, 2000) . However, ISC is the safest method of managing neurogenic urinary dysfunction in patients with SCI in terms of urological complications (Wyndaele, 2002) , and infection risk can be lowered by reducing the frequency of catheterization and avoiding bladder overfilling (Brittain, Peet, Potter, & Castleden, 1999; Gomelsky, Lemack, Weld, & Dmochowski, 2003) by using hydrophilic catheters or a new catheter with each process. Because ISC involves self-catheterization, patients (or their caregivers) must be motivated and have good coordination and cognitive function for successful catheterization. Done well, the advantages of ISC include autonomy, freedom, and lower risk of infection and stones compared with long-term indwelling catheters. Nursing tricks to teaching ISC in those with neurologic issues include getting the patients to catheterize initially when in a semirecumbent position with legs propped, with the catheter draining into a basin. Women should be taught to pull up the hood of the clitoris/labia to rotate the urethral meatus to the vaginal opening; the patients can be encouraged to do this by touch (the meatus feels like the tip of the nose). For men, the use of lidocaine jelly can help to improve comfort with catheterizing in the initial learning stage.
Once the patient is catheterized, it is important to log all findings (diary and bladder scan) to establish the optimal catheterization frequency (Weld & Dmochowski, 2000) . The key is to catheterize as infrequently as possible while still avoiding overflow incontinence; if the patient is leaking in between catheterizing, suspect either infection or that they need to catheterize more frequently. If there is no leaking and no tendency to recurrent UTI, the patient may be able to manage with fewer catheterizations (two or three times daily or sometimes once daily at bedtime is sufficient). Recurrent infections or infections unresponsive to antibiotics may be a sign of stones, as the rough surface of the stones serves as a nidus for infection.
Before instituting catheterization, the nurse should assess carefully whether the patient is able to partially empty during the day using a Crede maneuver (a nonforceful, smooth even pressure from the umbilicus to the lowest part of the abdomen) repeated several times to empty the bladder. This procedure should not be used in patients with detrusor overactivity because it can lead to urine passing from the bladder to the kidneys (Dowling-Castronovo & Bradway, 2003; Perry & Perry, 2002) .
Long-Term Indwelling Catheters Urethral Catheter (Foley)
An indwelling urethral (Foley) catheter may be required to relieve urinary retention in immobile patients. However, there are a number of complications with long-term use (increased rates of bladder cancer, infection, and sensitivity to components used in the catheter), and it is contraindicated in patients with urge incontinence (Table 2 ). The catheter is typically changed once a month by a nurse or a doctor. Use the smallest balloon/diameter catheter possible because bigger balloons take up more of the capacity and increase irritability of bladder. For women, using an estrogen cream at the meatus or an estradiol vaginal ring (Estring) will improve comfort and closure of the urethra around the catheter as well as potentially decreasing the risk of infection as it improves the vaginal environment.
Suprapubic Catheter
A suprapubic catheter is inserted into the bladder through a small abdominal incision below the umbilicus usually using a local anesthetic. A suprapubic catheter is an alternative to urethral catheterization for long-term use, often used in patients with SCI (Weld & Dmochowski, 2000) . Suprapubic catheters are easier to change than a Foley catheter because of accessibility but have a similar risk of bladder cancer, stone formation, allergic reactions, skin breakdown, bladder irritability, and bleeding as well as requiring a surgical procedure to insert (Perrin, Penfold, & McLeish, 1997) . However, there is a significantly decreased rate of infection in suprapubic versus urethral catheters (Ku, 2006) .
Treatment for Both Storage and Emptying Problems
Appropriate treatment relies on knowing the etiology of the problem, which demands urodynamic testing. If retention is related to pelvic floor prolapse, BPH, or pelvic muscle spasm, these underlying issues must be addressed before addressing the associated urgency. A common error in treatment of people with neurologic issues is to initiate anticholinergic medication without knowing the etiology of the urinary frequency; this can lead to worsening of retention and subsequent reflux. Prolapse in this population can be treated conservatively with pessaries, judicious application of pelvic floor electrical stimulation, and identification and rehabilitation of the pelvic floor muscles using electromyography biofeedback. BPH can be treated either surgically or medically depending on the severity, and pelvic muscle spasm can be treated medically with !-adrenergic blockade or muscle relaxants, via stents or with pelvic floor training using electrical stimulation or an implantable electrical nerve stimulation device. Occasionally, external sphincterotomy or urethral dilatation is used, although both of these treatments are methods of last resort as they can lead to incontinence being permanently exacerbated. An external sphincterotomy involves transurethral incision of the external urethral sphincter to weaken the sphincter muscle, whereas urethral dilatation refers to a process that gently stretches or dilates the urethra using a balloon or a series of graduated dilators.
Another option for pelvic floor spasm, which is vastly underused, is referral to physical therapy. Physical therapists not only treat the spasm but also address the underlying cause, such as malrotation of the hips or spinal column, myofascial scar tissue formation, and unilateral weakness while improving core strength and addressing balance issues so prevalent in this population. Once the issues associated with outlet obstruction are addressed, bladder function can then be evaluated and an accurate determination of bladder tone determined. If the bladder is truly hypotonic or areflexic and retention is not related to one of the above causes, then ISC is the treatment of choice. In some patients, a small capacity, hypotonic bladder is found, in which case it would be appropriate to consider the use of combined ISC and anticholinergic medication therapy.
Surgery
Surgical procedures to improve emptying include sphincterotomy (Lai, Hsu, Teh, Butler, & Boone, 2007) and placement of urethral stents (Edlund, Peeker, & Fall, 2001; Hasan, Marshall, Robson, & Neal, 1995) . Surgical procedures for improving bladder storage and incontinence include bladder augmentation (cystoplasty; Dik, Tsachouridis, Klijn, Uiterwaal, & de Jung, 2003; Docimo, 2000; Hoebeke, De Kuyper, Goeminne, Van Laecke, & Everaert, 2000) , complete bladder neck closure (Appell, 1998) , and detrusor myomectomy (Table 2 ; Game et al., 2000) .
Surgical treatment of bladder dysfunction in this population is associated with a high rate of complications (Fontaine et al., 1996) and should be considered only after all other options have been exhausted, that is, in patients in whom nonsurgical treatments are contraindicated or unsuccessful.
Augmentation of the capacity of the bladder by adding an additional Bpatch,[ which is harvested from the bowel to the bladder dome, is a major surgical procedure associated with a long recovery period and abdominal scarring. An alternative procedure is bladder autoaugmentation (Figure 3) , whereby native urothelial tissue is used to improve compliance, although increase in bladder capacity is limited.
Complications of cystoplasty include bacteriuria, absorption disorders, stones, and potential risk of malignancy (Venn & Mundy, 1998) . Consideration and discussion of future potential outcomes is an important role for the nurse caring for these patients. Patients should be made aware of the need for ISC after surgery and informed of possible complications. If the procedure involves complete bladder neck closure to prevent urinary leaking, an alternative way to empty the bladder will be required; frequently, a Mitrofanoff procedure/augmentation is performed with subsequent ISC through the umbilicus. Cystoplasty is not recommended in MS patients with recurrent UTI because it increases the risk of UTI further. However, despite these challenges and risks, cystoplasty is very effective and has a very high patient satisfaction rate in suitable patients (Herschorn & Hewitt, 1998) . In a 3-year study in 267 patients undergoing augmentation cystoplasty for neuropathic bladder or idiopathic detrusor overactivity, a continence rate of up to 93% was observed; however, longterm follow-up is required to ensure prompt treatment of the complications (Venn & Mundy, 1998) .
Previous surgery for incontinence can lead to chronic retention problems, which can also be corrected surgically using the transurethral bladder neck resection procedure (Game et al., 2000) . It is important to remember that the underlying neurologic disease can cause changes in the condition and function of the urinary system. This is especially pertinent in patients with degenerative diseases such as MS or Parkinson disease. Although the patient may present initially with urinary frequency because of small capacity, over time, as the disease progresses, they can develop a hypotonic, large capacity bladder.
Repair of the urethral sphincter can be done with the typical repairs used for stress incontinence. However, the patient must have a thorough urodynamic evaluation presurgery to evaluate bladder tone and function and be monitored for acute urinary retention postoperatively. If the patient shows any indication of compromised detrusor tone or inability to empty before surgery, a more conservative approach, such as bulking agents, could be considered instead.
Electrical Nerve Stimulation
Electrical nerve stimulation is a relatively new treatment modality that uses a pulse generator and an electrode to stimulate either the central nervous system or the peripheral nervous system to block impulses coming from the bladder or, in the case of peripheral stimulation systems, to increase muscle tone and strength of bladder neck contractions (Bernstein & Peters, 2005; Bower & Yeung, 2004; Edlund et al., 2004; Lavano et al., 2004; MaLossi & Chai, 2002; Sutherland et al., 2007; Vignes, De Seze, Dobremez, Joseph, & Guerin, 2005) . Central systems, via electrical stimulation of the sacral nerve, are surgically implanted but once implanted require less patient effort to use. Peripheral systems, which involve direct electrical stimulation of the pelvic floor via a rectal or vaginal probe, serve the dual purposes of increasing pelvic floor tone while calming bladder irritability but require manual dexterity and a greater degree of patient motivation. Other peripheral stimulation systems using percutaneous tibial nerve stimulation cannot be self-administered and require repeated courses of treatment to maintain the effect.
Sacral Nerve Stimulation
Central sacral nerve stimulation (SNS) can be used in the treatment of frequency, urgency, urge incontinence, and urinary retention. It has been found to be effective in patients unresponsive to pharmacotherapy as a less radical alternative to surgery (Kachourbos & Creasey, 2000) . Initial testing of SNS can be performed noninvasively via a temporary percutaneous placement of the electrode followed by surgical implantation of an electrical neurostimulator when the technique has been found to be successful in the individual patient. Once implanted, the device can be controlled by the patient using a portable programmer as required (Figure 4 ). These devices require close monitoring by the nursing staff for optimal control of symptoms. Improvement is monitored via diary and follow-up with the patient. An advantage to this treatment modality is the ability to shut down the equipment if issues evolve. A disadvantage, however, is that the batteries will require changing every 3 to 5 years and this will require surgery. Although implantation of the neurostimulator electrode requires a surgical procedure, this procedure is minor and the use of local anesthesia and recovery time is minimal. The associated risks are fairly low, other than those of electrode migration, but good results depend on accurate placement, which in turn depends on the surgeon's experience and ability. Little information or study data are available to demonstrate the efficacy of SNS in patients with specific neurogenic bladder issues, so SNS should be recommended with extreme caution in such populations.
Peripheral Nerve Stimulation
Portable systems providing transcutaneous (noninvasive) electrical stimulation of the bladder muscle can give the patient increased freedom and independence and reduced feelings of social isolation, but efficacy with these systems has been limited to date (O'Reilly et al., 2008) . Pelvic floor stimulation (PFS), a more conservative noninvasive form of electrical nerve stimulation, uses a vaginal or rectal electrode to directly stimulate contraction of the pelvic floor. PFS has the advantage that it is temporary, used for just 15 minutes daily, can be self-administered and will increase pelvic floor tone while improving symptoms of urgency and frequency (especially useful for those patients with mild-to-moderate mixed incontinence associated with stress incontinence). For those with chronic constipation, direct stimulation of the pelvic floor has the added benefit of improving regularity of evacuation. This therapy can be used in conjunction with Kegel exercises in patients with very weak pelvic floor muscle tone to improve pelvic muscle tone and thus stress incontinence. PFS has also been advocated in patients with neurogenic bladder dysfunction because of MS (De Ridder, Vermeulen, Ketelaer, Van Poppel, & Baert, 1999) .
In an open-label prospective trial, PFS was shown to improve clinical and neurological parameters in 30 women with MS; at 1 month, significant improvements were observed in the strength of the pelvic floor ( p G .001), endurance score ( p G .001), exhaustibility score ( p = .01), mean functional bladder capacity ( p = .005), mean urinary frequency ( p G .01), and mean number of daily incontinent episodes ( p G .01; De Ridder et al., 1999) . In a recent study, a combination of pelvic floor electrical stimulation, pelvic floor training, and electromyography biofeedback was effective in alleviating bladder dysfunction in women with MS (McClurg, Ashe, Marshall, & Lowe-Strong, 2006) . Percutaneous peripheral tibial nerve stimulation, using a needle electrode to transmit an electrical impulse to the sacral nerve plexus via the tibial nerve, has also been used successfully, with most patients reporting a reduction in urgency, frequency, pain, and urge incontinence after a course of 12 onceweekly, 30-minute treatments (Govier, Litwiller, Nitti, Kreder, & Rosenblatt, 2001; Vandoninck et al., 2003) . As with other electrical nerve stimulation therapy, the effects diminish over time and patients require regular maintenance treatment.
Conclusion
Neurogenic urinary dysfunction is a common feature of neurological conditions and has a major impact on morbidity and quality of life. A multifaceted, individualized management strategy, incorporating medical, educational, and psychosocial components, is required to achieve optimum outcomes for patients and their caregivers. Accurate diagnosis and selection of the most appropriate treatments from the various options available are crucial in providing the individual patient with the best possible improvement in quality of life. Therefore, the nursing role in the assessment, diagnostic work-up, treatment, monitoring, and educational support of patients with neurological disorders and associated urinary dysfunction and their caregivers is a key driver of successful management.
